Loading clinical trials...
Loading clinical trials...
A Phase 1b Open-Label, Dose-Escalating Study to Evaluate the Safety and Tolerability of PLG0206 in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Occurring After Total Knee Arthroplasty (TKA)
Conditions
Interventions
PLG0206
Locations
12
United States
Stanford Hospital
Palo Alto, California, United States
Gulfcoast Research
Sarasota, Florida, United States
LifeBridge
Baltimore, Maryland, United States
Brigham & Women's Hospital
Boston, Massachusetts, United States
NYU Langone Orthopedic Hospital
New York, New York, United States
Cleveland Clinic
Cleveland, Ohio, United States
Start Date
March 31, 2022
Primary Completion Date
March 19, 2024
Completion Date
March 19, 2024
Last Updated
May 21, 2025
NCT07406893
NCT05169229
NCT06827496
NCT06062251
NCT05927311
NCT06464770
Lead Sponsor
Peptilogics
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions